Supreme Court Allows Cross-Examination on Brand Use Despite Written Statement Not Being on Record  ||  Supreme Court: Enquiry Needed Before Dismissal for Suppressing Criminal Antecedents  ||  Supreme Court: Trading While Holding Confidential Information Indicates Insider Trading  ||  Supreme Court Explains Four-Step Test to Quash Criminal Cases Using Defence Material  ||  Supreme Court Acquits Man in Minor Rape Case, Flags HC's Medical Evidence Lapse  ||  Bombay HC: Minor’s Inability to Describe Sexual Act No Ground to Reject Her Testimony  ||  Delhi HC: Wife’s Interim Maintenance Cannot be Based Solely on Husband’s Income  ||  Calcutta HC: SLSA Cannot Adopt ‘Big Brother’ Approach Over Adult Victims’ Compensation  ||  Allahabad HC: Further Investigation Permissible Even After Final Report is Accepted  ||  Allahabad HC: Court-Directed Award Cannot be Challenged for Not Computing Market Value    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved